XIN RU: Open Payments
NPI 1952008906 · SAN JOSE, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$552 in 22 payments from 6 companies in 2025. Trend: 2023 $329 · 2024 $425 · 2025 $552
Food & beverage: $552
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 13 | $328 |
| Bayer Healthcare Pharmaceuticals Inc. | 4 | $95 |
| Amgen Inc. | 2 | $41 |
| Alnylam Pharmaceuticals Inc. | 1 | $32 |
| Novartis Pharmaceuticals Corporation | 1 | $29 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 1 | $25 |
Products named: Wegovy, Kerendia, Repatha, AMVUTTRA, LEQVIO, Ozempic, JARDIANCE.
Industry payments across CA — which companies pay providers there.
